FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPR	OVAL						
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>TILTON GLENN F</u>					2. Issuer Name and Ticker or Trading Symbol AbbVie Inc. [ABBV]									eck all appl	or	g Perso	10% Ov	vner	
(Last) (First) (Middle) 1 N. WAUKEGAN ROAD				3. Date of Earliest Transaction (Month/Day/Year) 12/31/2015										Office below	r (give title)		Other (s below)	specify	
(Street) NORTH CHICAGO				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(SI	tate) (Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transa Date (Month/Date)				Execution ay/Year) if any			Deemed ecution Date, ny onth/Day/Year)		3. Transaction Code (Instr. 8)		rities Acqu ed Of (D) (II	ired (A nstr. 3,	4 and Securit		es ially Following	Form:	Direct Indirect tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	t (A) or Pi		rice	Transac (Instr. 3	ction(s)			(5 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, Ti	4. Transacti Code (Ins 8)				6. Date Exercisab Expiration Date (Month/Day/Year)		•	nd 7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersh Form: y Direct (D or Indirec (I) (Instr.	wnership orm: irect (D)	Beneficial Ownership t (Instr. 4)
				С	ode	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amo or Num of Shar	ber					
Stock Equivalent Units	\$0 ⁽¹⁾	12/31/2015			A		582		(1)	T	(1)	Common Stock	58	2	\$59.24	23,067 ⁽²⁾) [D	

Explanation of Responses:

- 1. Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
- 2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Steven L. Scrogham, attorney-01/05/2016 in-fact for Glenn F. Tilton

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.